Veeva Systems Inc. Reports Strong Q1 Results Fueled by AI Advancements

In the first quarter ended April 30, 2026, Veeva reported total revenues of $882.9 million, marking a 16% year-over-year increase from $759.0 million in the same period last year. Subscription revenues also saw a substantial rise, reaching $730.2 million, a 15% increase from $634.8 million in the prior year.

Veeva's operating income for the quarter was $273.1 million, up 17% from $233.7 million a year ago. Meanwhile, the non-GAAP operating income reached $395.4 million, reflecting a 13% increase over the previous year’s $349.9 million.

The net income figures were equally impressive. Veeva reported a net income of $260.9 million, up 14% from $228.2 million last year, while the non-GAAP net income was $371.1 million, an increase of 13% from $327.8 million.

Veeva’s earnings per share also saw an uptick. The fully diluted net income per share was $1.57, compared to $1.37 in the previous year, indicating a growth trajectory. The non-GAAP fully diluted net income per share improved to $2.24, up from $1.97 a year prior.

“Our rapid progress with Veeva AI sets the foundation as we enter the next chapter of our industry cloud,” stated CEO Peter Gassner. He emphasized that Veeva is transforming from an industry-specific application company into both an application and an AI agent company. This shift is poised to assist customers in delivering medicines to patients more swiftly and efficiently.

The quarter saw significant strides in Veeva's AI initiatives. The acquisition of Ostro in March has enabled the company to provide compliant, conversational AI for over 50 brands. The rollout of Vault AI is on track to expand across all Vault applications by August, while the new Veeva Falcon platform aims to facilitate clinical, regulatory, and safety processes with an early adopter release scheduled for November.

At the recent Commercial Summit held in May, Veeva unveiled its vision for Agentic Commercial, leveraging AI to optimize the delivery of medicines to patients. Tools like the Agentic Call Report in Vault CRM and Ostro's conversational AI are designed to enhance the commercial evidence generation process. In the first quarter, Veeva added 27 new Vault CRM customers, bringing the total to over 150 live customers.

Looking ahead, Veeva has issued guidance for a strong fiscal second quarter ending July 31, 2026, expecting total revenues to fall between $902 million and $905 million. Non-GAAP operating income is projected to be between $392 million and $395 million, with non-GAAP fully diluted net income per share estimated between $2.21 and $2.22.

For the fiscal year ending January 31, 2027, Veeva has updated its guidance to reflect total revenues of approximately $3.635 billion to $3.645 billion and non-GAAP operating income of about $1.610 billion. Non-GAAP fully diluted net income per share is anticipated to be around $9.05.

With a solid first quarter performance and ambitious plans to integrate AI into its operations, Veeva Systems Inc. is well-positioned to capitalize on the growing opportunities in the life sciences sector. The company's commitment to innovation and customer success continues to drive its growth trajectory, making it a key player in the industry’s evolution.

For more information, Veeva will host a Q&A conference call today at 2:00 p.m. PT to discuss these results in detail. The call will be accessible via their investor relations website.